Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01441687 · ClinicalTrials.gov registry record · NA

Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome

A NA study of Healthy and Prostate Cancer, sponsored by City of Hope Medical Center.

Active
Registry status
NA
Development phase
243
Enrollment target
5
Study locations

NCT01441687: Active NA study of Healthy and Prostate Cancer, sponsored by City of Hope Medical Center.

NCT01441687 is a NA study of Healthy and Prostate Cancer that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 243 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (62% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01441687, a NA study of Healthy and Prostate Cancer, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
243 participants
Enrollment target
5
Study locations

Study Summary

This randomized pilot phase I trial studies the best way, either expressed prostatic secretion (EPS) or post massage urine (PMU) biomarkers, of predicting biopsy results in patients undergoing prostate biopsy. Studying samples of urine in the laboratory may help doctors detect prostate cancer. It is not yet known whether EPS or PMU biomarkers are more effective in predicting prostate biopsy results

Primary Outcome

Compare assay results in 300 EPS specimens with those from 300 PMU specimens. The gold standard for assay validity is the biopsy result.

Interventions

  • OTHER laboratory biomarker analysis
  • PROCEDURE transrectal prostate biopsy

Study Locations (5)

California

  • Chinn & Chinn Urology Associates, Inc. - Arcadia
  • City of Hope Medical Center - Duarte
  • Citrus Valley Urologic Medical Group - Glendora
  • Dr. Felix Chi-Ming Yip - Monterey Park
  • City of Hope- South Pasadena Cancer Center - South Pasadena

Trial Details

FieldValue
Enrollment Target 243 participants
Start Date 2009-07-14
Est. Completion 2027-02-03
Phase NA
City of Hope Medical Center

582 total trials

What the registry record for NCT01441687 still lists

NCT01441687 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (62% lower).

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.

NCT01441687 lists 5 locations in 1 state (California).

Frequently Asked Questions

What is clinical trial NCT01441687 about?

NCT01441687 is a clinical study titled "Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome". This randomized pilot phase I trial studies the best way, either expressed prostatic secretion (EPS) or post massage urine (PMU) biomarkers, of predicting biopsy results in patients undergoing prostate biopsy. Studying samples of urine in the laboratory may help doctors detect prostate cancer. It is...

What is the current status of trial NCT01441687?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 243 participants. The study started on 2009-07-14. Estimated completion is 2027-02-03.

What conditions does trial NCT01441687 study?

This clinical trial studies the following conditions: Healthy, Prostate Cancer, Conditions Influencing Health Status.

What interventions are being tested in trial NCT01441687?

The interventions under investigation include: laboratory biomarker analysis (OTHER), transrectal prostate biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT01441687?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01441687 being conducted?

This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01441687's enrollment target sits among peer trials

243 102nd of 1090 higher than 989 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06253871 · 243 participants · Phase 1

    A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • NCT06289491 · 243 participants · NA

    A Trial of Hydrus Microstent Versus Goniotomy

  • NCT06536296 · 243 participants · NA

    The Impact of Music Medicine on Preterm Brain Development and Behavior

  • NCT06907615 · 243 participants · Phase 2

    A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01441687, the US trial registry maintained by the National Library of Medicine. NCT01441687 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.